الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
Background; Inflammatory bowel diseases (IBDs) are idiopathic diseases
caused by the destruction of the mucosa gastrointestinal tract by the mucosal
immune system. The main types of inflammatory bowel disease are Crohn’s
disease (CD) and ulcerative colitis (UC).
Aim and objectives; To determine the serum concentrations of visfatin in
newly diagnosed IBD patients, to evaluate its role in the diagnosis of IBD, and
to correlate it with disease activity and colonoscopic findings .
Subjects and methods; This was a case-control study that was conducted in a
gastroenterology outpatient clinic,Alex Fever Hospital over 90 studied subjects
were divided into three groups.
Results; As regards serum visfatin, there was a statistically significant
difference between Crohn’s disease, ulcerative colitis, and control groups
(p2<0.001). The Post Hoc test revealed that the Crohn’s disease group had a
significantly higher serum visfatin level (3.7 ± 2.43) than the control group
(1.26 ± 0.79), (p3<0.001). Moreover, ulcerative colitis had a significantly
higher serum visfatin level than the control group with means of 4.04 ± 2.19 and
1.26 ± 0.79 respectively, (p<0.001). However, there was no statistically
significant difference between Crohn’s disease and ulcerative colitis with means
of 3.7 ± 2.43 and 4.04 ± 2.19 respectively (p1=0.441).there were no
significantdifferences between Crohn’s disease and Ulcerative colitis as regards
serum visfatin with meansof 3.7 ± 2.43 and 4.04 ± 2.19 respectively. there was
no significant difference between Crohn’s disease (A2 and A3) as regards fecal
calprotectin and serum visfatin.there was no significant difference between
Crohn’s disease (L1 and L3) as regards fecal calprotectin and serum visfatin.